Einzeltreffer — DigiBib

A checkpoint protein called the V-domain Ig suppressor of T cell activation (VISTA) is important for controlling immune responses. Immune cells that interact with VISTA have molecules, or receptors, known as VISTA receptors. Immune system activity can be modified by the interaction between VISTA and its receptors. Since targeting VISTA or its receptors may be beneficial in certain conditions, VISTA has been studied in relation to immunotherapy for cancer and autoimmune illnesses. The purpose of this study was to examine the expression levels and interactions between VISTA and its receptors, VSIG3 and PSGL-1, in breast cancer tissues. IHC analysis revealed higher levels of proteins within the VISTA/VSIG3/PSGL-1 axis in cancer tissues than in the reference samples (mastopathies). VISTA was found in breast cancer cells and intratumoral immune cells, with membranous and cytoplasmic staining patterns. VISTA was also linked with pathological grade and VSIG3 and PSGL-1 levels. Furthermore, we discovered that the knockdown of one axis member boosted the expression of the other partners. This highlights the significance of VISTA/VSIG3/PSGL-1 in tumor stroma and microenvironment remodeling. Our findings indicate the importance of the VISTA/VSIG3/PSGL-1 axis in the molecular biology of cancer cells and the immune microenvironment.

Titel:	The VISTA/VSIG3/PSGL-1 axis: crosstalk between immune effector cells and cancer cells in invasive ductal breast carcinoma.
Autor/in / Beteiligte Person:	Olbromski, M ; Mrozowska, M ; Piotrowska, A ; Smolarz, B ; Romanowicz, H
Zeitschrift:	Cancer immunology, immunotherapy : CII, Jg. 73 (2024-06-04), Heft 8, S. 136
Veröffentlichung:	Berlin : Springer Verlag ; <i>Original Publication</i>: Berlin ; New York, NY : Springer International, c1982-, 2024
Medientyp:	academicJournal
ISSN:	1432-0851 (electronic)
DOI:	10.1007/s00262-024-03701-w
Schlagwort:	Humans Female Tumor Microenvironment immunology Middle Aged Breast Neoplasms immunology Breast Neoplasms pathology Breast Neoplasms metabolism Membrane Glycoproteins metabolism Membrane Glycoproteins immunology B7 Antigens metabolism Carcinoma, Ductal, Breast immunology Carcinoma, Ductal, Breast pathology Carcinoma, Ductal, Breast metabolism
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article Language: English [Cancer Immunol Immunother] 2024 Jun 04; Vol. 73 (8), pp. 136. <i>Date of Electronic Publication: </i>2024 Jun 04. MeSH Terms: Breast Neoplasms* / immunology ; Breast Neoplasms* / pathology ; Breast Neoplasms* / metabolism ; Membrane Glycoproteins* / metabolism ; Membrane Glycoproteins* / immunology ; B7 Antigens* / metabolism ; Carcinoma, Ductal, Breast* / immunology ; Carcinoma, Ductal, Breast* / pathology ; Carcinoma, Ductal, Breast* / metabolism ; Humans ; Female ; Tumor Microenvironment / immunology ; Middle Aged References: Front Immunol. 2021 Mar 25;12:625808. (PMID: 33841409) ; Trends Immunol. 2021 Mar;42(3):209-227. (PMID: 33495077) ; Cancers (Basel). 2023 Apr 17;15(8):. (PMID: 37190254) ; Front Oncol. 2023 Jul 05;13:1197168. (PMID: 37476378) ; Breast Cancer (Dove Med Press). 2023 Jul 28;15:525-540. (PMID: 37533589) ; CA Cancer J Clin. 2022 Nov;72(6):524-541. (PMID: 36190501) ; J Cancer Res Clin Oncol. 2021 Feb;147(2):517-531. (PMID: 33237432) ; Cancer. 2022 Nov 15;128(22):3905. (PMID: 36321768) ; J Hematol Oncol. 2023 Feb 27;16(1):15. (PMID: 36849939) ; Genes (Basel). 2023 Jun 28;14(7):. (PMID: 37510269) ; Transl Cancer Res. 2023 Jul 31;12(7):1826-1835. (PMID: 37588736) ; Nat Commun. 2022 Dec 5;13(1):7495. (PMID: 36470901) ; Cancer Immunol Res. 2014 Jun;2(6):510-7. (PMID: 24894088) ; Int J Oncol. 1995 Apr;6(4):773-81. (PMID: 21556602) ; Sci Rep. 2020 Sep 16;10(1):15171. (PMID: 32938950) ; PLoS Genet. 2012;8(8):e1002899. (PMID: 22916035) ; Front Immunol. 2021 May 19;12:676181. (PMID: 34093577) ; Naunyn Schmiedebergs Arch Pharmacol. 2021 Jun;394(6):1057-1065. (PMID: 33616679) ; Mol Cancer Res. 2020 Jun;18(6):938. (PMID: 32487678) ; Clin Med Insights Oncol. 2022 Nov 2;16:11795549221134831. (PMID: 36338263) ; J Cancer Res Clin Oncol. 2023 Jul;149(7):4131-4139. (PMID: 36042047) ; Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1692-1697. (PMID: 30635425) ; Clin Biochem. 2011 Sep;44(13):1128-1136. (PMID: 21704611) ; Cancer Sci. 2005 Aug;96(8):498-506. (PMID: 16108831) ; Adv Surg. 2023 Sep;57(1):1-14. (PMID: 37536846) ; Cancer Treat Rev. 2023 Apr;115:102527. (PMID: 36893691) ; Front Oncol. 2021 Jan 11;10:583966. (PMID: 33505908) ; Immunology. 2019 Jan;156(1):74-85. (PMID: 30220083) ; Front Oncol. 2021 Feb 02;10:608609. (PMID: 33604291) ; Strahlenther Onkol. 2023 Aug;199(8):761-772. (PMID: 36862156) ; Front Oncol. 2021 Apr 16;11:658488. (PMID: 33937071) ; Oncoimmunology. 2020 Oct 20;9(1):1830524. (PMID: 33150045) ; ESMO Open. 2020 Jun;4(Suppl 3):e000683. (PMID: 32554470) ; Immunotherapy. 2022 Apr;14(6):419-431. (PMID: 35187955) ; Cancer Biomark. 2023;38(1):37-47. (PMID: 37522197) ; Geburtshilfe Frauenheilkd. 2023 Mar 09;83(3):299-309. (PMID: 36908287) ; Cancer Cell Int. 2023 Nov 7;23(1):265. (PMID: 37936192) ; Sci Adv. 2021 Jul 14;7(29):. (PMID: 34261648) ; Int J Mol Sci. 2020 Apr 10;21(7):. (PMID: 32290171) ; Commun Biol. 2021 Jul 23;4(1):906. (PMID: 34302042) ; Cancers (Basel). 2021 Mar 19;13(6):. (PMID: 33808627) ; Mol Cancer Res. 2020 Jun;18(6):939. (PMID: 32487679) ; Immunotherapy. 2022 Oct;14(14):1121-1131. (PMID: 36047777) ; Biomark Res. 2022 Jul 13;10(1):49. (PMID: 35831836) ; Bone Res. 2020 Feb 10;8:5. (PMID: 32047704) ; Immunotargets Ther. 2021 Jun 22;10:185-200. (PMID: 34189130) ; BMC Cancer. 2023 Jul 14;23(1):661. (PMID: 37452272) ; Bosn J Basic Med Sci. 2022 Sep 16;22(5):707-715. (PMID: 35122478) ; Life Sci. 2022 Dec 1;310:121083. (PMID: 36265568) ; Mol Cancer Res. 2022 Jul 6;20(7):1178. (PMID: 35791690) ; Environ Int. 2023 Aug;178:108112. (PMID: 37517180) ; Front Immunol. 2024 Jan 30;15:1283364. (PMID: 38357542) ; Cancer Cell Int. 2014 May 16;14:41. (PMID: 24883045) ; Oncoimmunology. 2017 Feb 21;6(4):e1293215. (PMID: 28507801) ; Biomed Res Int. 2017;2017:6138145. (PMID: 28680883) ; Front Immunol. 2021 Feb 23;12:636238. (PMID: 33708224) ; Front Oncol. 2023 Apr 20;13:1154631. (PMID: 37152039) ; Cancer Immunol Res. 2019 Jul;7(7):1079-1090. (PMID: 31088847) ; Nature. 2019 Oct;574(7779):565-570. (PMID: 31645726) ; Cell Rep. 2020 Jan 14;30(2):510-524.e6. (PMID: 31940493) ; J Hematol Oncol. 2020 Jun 29;13(1):83. (PMID: 32600443) ; Biochem Pharmacol. 2023 Jun;212:115545. (PMID: 37044296) ; Mol Cancer Res. 2017 Apr;15(4):467-477. (PMID: 28108624) ; Cancer Immunol Immunother. 2018 Jul;67(7):1113-1121. (PMID: 29737375) ; Nat Neurosci. 2016 Jan;19(1):84-93. (PMID: 26595655) ; J Immunother Cancer. 2022 Feb;10(2):. (PMID: 35131861) ; PLoS One. 2023 Mar 23;18(3):e0278849. (PMID: 36952478) ; Am J Transl Res. 2021 Sep 15;13(9):10428-10438. (PMID: 34650712) ; J Biotechnol. 2017 Oct 20;260:18-30. (PMID: 28867483) ; Biochem Pharmacol. 2023 Apr;210:115492. (PMID: 36898416) ; Front Immunol. 2024 Jan 23;15:1365240. (PMID: 38322267) ; Gene. 2024 Feb 20;896:148043. (PMID: 38042220) Contributed Indexing: Keywords: Breast cancer; CD45; CD68; PSGL-1; VISTA; VSIG3/IGSF11 Substance Nomenclature: 0 (VSIR protein, human) ; 0 (Membrane Glycoproteins) ; 0 (B7 Antigens) ; 0 (P-selectin ligand protein) Entry Date(s): Date Created: 20240604 Date Completed: 20240604 Latest Revision: 20240607 Update Code: 20240607 PubMed Central ID: PMC11150347

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

The VISTA/VSIG3/PSGL-1 axis: crosstalk between immune effector cells and cancer cells in invasive ductal breast carcinoma.